Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2022 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
November 03, 2022 17:00 ET | Source: XORTX Therapeutics Inc.

XORTX Presents New Proof of Concept Data at American Society of Nephrology

● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increasein Total Kidney Weight in Polycystic Kidney Disease ● CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX...
November 03, 2022 10:15 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Participation at Upcoming Investor Conferences

CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
October 26, 2022 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Receives Further No Objection Letter from Health Canada

CALGARY, Alberta, Oct. 26, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
October 25, 2022 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Sponsored American Society of Nephrology Study Abstract Available Online

• Chronically Increased Uric Acid Accelerates Structuraland Functional Changes in Polycystic Kidney Disease • CALGARY, Alberta, Oct. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc....
October 07, 2022 18:02 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Closing of US$5 Million Public Offering

CALGARY, Alberta, Oct. 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
October 04, 2022 08:30 ET | Source: XORTX Therapeutics Inc.

XORTX Announces US$5 Million Public Offering

CALGARY, Alberta, Oct. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
September 19, 2022 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical...
September 01, 2022 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2022

CALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
August 22, 2022 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...